GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.
SUBSCRIBE
Biohealth Innovation
Founding Member of
Biohealth Innovation
GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of its shingles vaccine.